HK1250341A1 - 用於治療無效性紅細胞生成的方法和組合物 - Google Patents

用於治療無效性紅細胞生成的方法和組合物

Info

Publication number
HK1250341A1
HK1250341A1 HK18109792.1A HK18109792A HK1250341A1 HK 1250341 A1 HK1250341 A1 HK 1250341A1 HK 18109792 A HK18109792 A HK 18109792A HK 1250341 A1 HK1250341 A1 HK 1250341A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
ineffective erythropoiesis
treating ineffective
treating
Prior art date
Application number
HK18109792.1A
Other languages
English (en)
Inventor
Jasbir Seehra
Robert Scott Pearsall
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of HK1250341A1 publication Critical patent/HK1250341A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18109792.1A 2011-10-17 2018-07-30 用於治療無效性紅細胞生成的方法和組合物 HK1250341A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17

Publications (1)

Publication Number Publication Date
HK1250341A1 true HK1250341A1 (zh) 2018-12-14

Family

ID=48141315

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15104178.9A HK1203413A1 (zh) 2011-10-17 2015-04-30 用於治療無效性紅細胞生成的方法和組合物
HK18109792.1A HK1250341A1 (zh) 2011-10-17 2018-07-30 用於治療無效性紅細胞生成的方法和組合物
HK18112295.7A HK1252940A1 (zh) 2011-10-17 2018-09-26 用於治療無效性紅細胞生成的方法和組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15104178.9A HK1203413A1 (zh) 2011-10-17 2015-04-30 用於治療無效性紅細胞生成的方法和組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18112295.7A HK1252940A1 (zh) 2011-10-17 2018-09-26 用於治療無效性紅細胞生成的方法和組合物

Country Status (13)

Country Link
US (4) US20130243743A1 (zh)
EP (3) EP3520805B1 (zh)
JP (4) JP6092883B2 (zh)
KR (4) KR20140084211A (zh)
CN (3) CN107837390A (zh)
AU (4) AU2012326207B2 (zh)
BR (3) BR112014009528B1 (zh)
CA (1) CA2852683A1 (zh)
DK (1) DK3520805T3 (zh)
EA (2) EA202090053A3 (zh)
ES (2) ES2741477T3 (zh)
HK (3) HK1203413A1 (zh)
WO (1) WO2013059347A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
AU2010263182B2 (en) 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
WO2011031901A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
AU2015231022B2 (en) * 2014-03-21 2021-02-04 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin B and/or GDF11
JP6649895B2 (ja) * 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
TN2016000553A1 (en) * 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
RS64214B1 (sr) * 2014-12-03 2023-06-30 Celgene Corp Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma
KR20180006386A (ko) 2015-04-22 2018-01-17 얼라이브젠 유에스에이 인코포레이티드 신규한 근육 소모 질환 치료용 하이브리드 ａｃｔｒｉｉｂ 리간드 트랩 단백질
US20180125928A1 (en) * 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
US11123430B2 (en) * 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
EP3523328A4 (en) * 2016-10-05 2020-04-01 Acceleron Pharma Inc. ACTRIIB VARIANT PROTEINS AND USES THEREOF
CN110461349A (zh) 2016-11-10 2019-11-15 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN111050770A (zh) * 2017-06-14 2020-04-21 细胞基因公司 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
DE60027135T2 (de) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
JP2006510606A (ja) * 2002-10-15 2006-03-30 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TW201919685A (zh) * 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

Also Published As

Publication number Publication date
AU2018247262A1 (en) 2018-11-01
JP2014530253A (ja) 2014-11-17
ES2741477T3 (es) 2020-02-11
AU2017201580A1 (en) 2017-03-30
CN103987403B (zh) 2017-12-01
CA2852683A1 (en) 2013-04-25
JP2020186277A (ja) 2020-11-19
HK1252940A1 (zh) 2019-06-06
EA202090053A2 (ru) 2020-04-30
KR20140084211A (ko) 2014-07-04
EP3875104A1 (en) 2021-09-08
JP6383821B2 (ja) 2018-08-29
AU2012326207A1 (en) 2014-05-15
EA201490809A1 (ru) 2014-09-30
US20210207107A1 (en) 2021-07-08
US20130243743A1 (en) 2013-09-19
EP2797620A4 (en) 2015-05-20
EP2797620A1 (en) 2014-11-05
AU2018247262B2 (en) 2020-12-24
AU2012326207B2 (en) 2016-12-15
ES2869168T3 (es) 2021-10-25
CN103987403A (zh) 2014-08-13
BR112014009528A2 (pt) 2017-05-09
EA034563B1 (ru) 2020-02-20
CN107837390A (zh) 2018-03-27
AU2017201580B2 (en) 2018-07-12
JP6796626B2 (ja) 2020-12-09
BR112014009528B1 (pt) 2020-12-29
EP2797620B1 (en) 2019-04-24
JP2017101060A (ja) 2017-06-08
KR20200019261A (ko) 2020-02-21
CN107693776A (zh) 2018-02-16
BR122019023174B1 (pt) 2021-02-23
AU2020286229A1 (en) 2021-01-07
JP6092883B2 (ja) 2017-03-08
EA202090053A3 (ru) 2020-06-30
US20170327800A1 (en) 2017-11-16
JP2018165287A (ja) 2018-10-25
DK3520805T3 (da) 2021-04-19
KR20190105113A (ko) 2019-09-11
BR122019023166B1 (pt) 2021-02-23
KR102079482B1 (ko) 2020-02-19
EP3520805B1 (en) 2021-03-10
HK1203413A1 (zh) 2015-10-30
BR112014009528A8 (pt) 2019-12-10
WO2013059347A1 (en) 2013-04-25
KR20220075438A (ko) 2022-06-08
EP3520805A1 (en) 2019-08-07
US20170137791A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
HK1252940A1 (zh) 用於治療無效性紅細胞生成的方法和組合物
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1201475A1 (zh) 治療疼痛的方法和組合物
IL227429A0 (en) The components and methods of cancer treatment
EP2755482A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
EP2684167A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
ZA201404187B (en) Compositions and methods for treating dental conditions
EP2771341A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
HK1190936A1 (zh) 治療代謝綜合徵的方法和配方
DK3292875T3 (en) Compositions and methods for treating diseases
EP2766009A4 (en) METHOD AND COMPOSITIONS FOR SKIN TREATMENT
EP2800579A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL232648A0 (en) Preparations and methods for treating glioma
HK1208598A1 (zh) 治療疼痛的方法及組合物
IL229231A0 (en) Preparations and methods for the treatment of cancer
EP2723346A4 (en) COMPOSITIONS AND METHODS USEFUL FOR TREATING PEDICULOSIS
ZA201308683B (en) Methods and compositions suitable for preventing and treating hyperleptinemia
EP2714082A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
GB201122124D0 (en) Compositions and methods for treating biofilms
GB201104584D0 (en) Compositions and methods for treating biofilms